Covista Inc. filings document current reports on operating results, academic performance, investor communications and strategic progress for its healthcare education portfolio. Recent Form 8-K records furnish quarterly results releases, enrollment metrics, revenue and earnings measures, fiscal guidance, share repurchase activity, debt refinancing references and institutional updates for Chamberlain and Walden.
The company's Regulation FD disclosures also include investor newsletters describing milestones, partnerships, workforce-related initiatives and operational progress. Covista's filing record identifies public-company disclosure themes tied to results of operations, capital allocation, governance signatories, cautionary forward-looking statements and the company's current identity as a NYSE-listed healthcare educator.
Covista Inc. entered into an Amendment No. 5 to its Credit Agreement on March 2, 2026, creating new 2026 Term Loans with an aggregate original principal of $510 million maturing on March 2, 2033. These loans bear interest at Term SOFR plus 2.25% (with a 0.75% SOFR floor) or an alternate base rate plus 1.25%, and the amendment reduced term loan interest margins by 0.50%.
The company used the 2026 Term Loan proceeds to fully refinance existing term loans under the prior credit agreement and to redeem in full its 5.50% Senior Secured Notes due 2028. The redemption covered approximately $404,950,000 of principal at 100% of par plus accrued interest, after which the related indenture was fully satisfied and discharged.